Sort by
Refine Your Search
-
transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it
-
, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational
-
with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance
-
acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other
-
(e.g., Smith, John - Alnylam, GSK ) Please ask your letter writers to complete and submit the Letter of Recommendation Form along with their recommendation. Click here to access the form and share it
-
your teaching philosophy The College of the Holy Cross uses Interfolio to collect all faculty job applications electronically. Please submit all application materials to https://apply.interfolio.com
-
Chiesi Global Rare Diseases - Medical Affairs Postdoctoral Research Fellow | Northeastern University
, ophthalmology disorders and rare immunodeficiencies. The unit is also a dedicated partner with global leaders in scientific research, patient advocacy and care. No matter where your path starts at Chiesi, it
-
serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance
-
support the development of Alnylam's investigational RNAi therapeutics. Early Assets Medical Affairs partners with experts across the organization to guide each unique investigational program as it enters
-
Regulatory Fellowship is unique in that it offers the opportunity for a blended experience during the first year, encompassing both Strategy and Advertising, Promotion & Labeling. In the second year